SPOTLIGHT: CuraGen sells Belinostat stake to TopoTarget

CuraGen Corporation has sold its stake in Belinostat to TopoTarget for $39 million upfront in a combination of cash and stock. TopoTarget will now take full control of the cancer drug's development. "CuraGen has been a good partner and helped us over a high risk period," said Dr. Peter Buhl Jensen, CEO of TopoTarget. CuraGen said the move allows it to focus on other clinical programs. Release